A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

D. Park, C. Ryan, M. Dolan, N. Vogelzang, W. Stadler

    Research output: Contribution to journalArticle

    16 Scopus citations

    Abstract

    Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

    Original languageEnglish (US)
    Pages (from-to)160-162
    Number of pages3
    JournalCancer Chemotherapy and Pharmacology
    Volume50
    Issue number2
    DOIs
    StatePublished - Sep 12 2002

    Keywords

    • DNA repair
    • O-Alkylguanine-DNA alkyltransferase
    • Phase II trial
    • Renal cell cancer

    ASJC Scopus subject areas

    • Oncology
    • Toxicology
    • Pharmacology
    • Cancer Research
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'A phase II trial of oral temozolomide in patients with metastatic renal cell cancer'. Together they form a unique fingerprint.

  • Cite this